DNLI Denali Therapeutics Inc

Price (delayed)

$19.78

Market cap

$2.75B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.06

Enterprise value

$2.67B

Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing ...

Highlights
Denali Therapeutics's debt has decreased by 17% from the previous quarter and by 15% YoY
The EPS has soared by 59% YoY but it has decreased by 14% from the previous quarter
The net income has soared by 55% year-on-year but it is down by 17% since the previous quarter
The quick ratio has declined by 15% since the previous quarter
Denali Therapeutics's equity has decreased by 8% QoQ

Key stats

What are the main financial stats of DNLI
Market
Shares outstanding
139.16M
Market cap
$2.75B
Enterprise value
$2.67B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.65
Price to sales (P/S)
8.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.08
Earnings
Revenue
$330.53M
EBIT
-$145.19M
EBITDA
-$128.47M
Free cash flow
-$370.93M
Per share
EPS
-$1.06
Free cash flow per share
-$2.7
Book value per share
$7.46
Revenue per share
$2.41
TBVPS
$8.4
Balance sheet
Total assets
$1.15B
Total liabilities
$122.96M
Debt
$44.98M
Equity
$1.03B
Working capital
$986.16M
Liquidity
Debt to equity
0.04
Current ratio
13.65
Quick ratio
13.27
Net debt/EBITDA
0.64
Margins
EBITDA margin
-38.9%
Gross margin
100%
Net margin
-43.9%
Operating margin
-59.5%
Efficiency
Return on assets
-11.4%
Return on equity
-13.5%
Return on invested capital
-13.7%
Return on capital employed
-13.5%
Return on sales
-43.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DNLI stock price

How has the Denali Therapeutics stock price performed over time
Intraday
-2.13%
1 week
17.53%
1 month
12.9%
1 year
-27.15%
YTD
-7.83%
QTD
-7.83%

Financial performance

How have Denali Therapeutics's revenue and profit performed over time
Revenue
$330.53M
Gross profit
$330.53M
Operating income
-$196.7M
Net income
-$145.22M
Gross margin
100%
Net margin
-43.9%
Denali Therapeutics's net margin has soared by 85% YoY but it has decreased by 20% from the previous quarter
DNLI's operating margin has surged by 81% year-on-year but it is down by 20% since the previous quarter
The net income has soared by 55% year-on-year but it is down by 17% since the previous quarter
DNLI's operating income is up by 42% year-on-year but it is down by 16% since the previous quarter

Growth

What is Denali Therapeutics's growth rate over time

Valuation

What is Denali Therapeutics stock price valuation
P/E
N/A
P/B
2.65
P/S
8.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.08
The EPS has soared by 59% YoY but it has decreased by 14% from the previous quarter
DNLI's price to book (P/B) is 44% less than its 5-year quarterly average of 4.7 and 12% less than its last 4 quarters average of 3.0
Denali Therapeutics's equity has decreased by 8% QoQ
The stock's price to sales (P/S) is 80% less than its 5-year quarterly average of 42.0 and 45% less than its last 4 quarters average of 15.0
DNLI's revenue is down by 3% since the previous quarter

Efficiency

How efficient is Denali Therapeutics business performance
The ROS has soared by 85% YoY but it has decreased by 20% from the previous quarter
The return on invested capital has surged by 63% year-on-year but it has declined by 15% since the previous quarter
The return on equity has surged by 62% year-on-year but it has declined by 17% since the previous quarter
The return on assets has surged by 54% year-on-year but it has declined by 24% since the previous quarter

Dividends

What is DNLI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DNLI.

Financial health

How did Denali Therapeutics financials performed over time
DNLI's total liabilities has dropped by 71% year-on-year but it is up by 3.8% since the previous quarter
The company's total assets fell by 21% YoY and by 7% QoQ
Denali Therapeutics's debt is 96% less than its equity
DNLI's debt to equity is down by 20% since the previous quarter and by 20% year-on-year
Denali Therapeutics's debt has decreased by 17% from the previous quarter and by 15% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.